Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Bumetanide
Dapagliflozin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45
Exclusion Criteria:
- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
- Any significant acute or chronic medical illness
- Current or recent (within 3 months) gastrointestinal disease
- Current smoker or recent (within 1 month) history of regular tobacco use
- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population
- Abnormal urinalysis at screening
- Glucosuria at screening
- Abnormal liver functions tests (ALT, AST or total bilirubin > 10 % ULN)
- Presence of edema on physical exam
- History of diabetes mellitus
- History of heart failure
- History of renal insufficiency
- History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
- Positive urine screen for drugs of abuse either at screening or before dosing
- Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
- History of allergy to SGLT2 inhibitors, bumetanide (or related compounds)
- History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
- Prior exposure to dapagliflozin within 3 months of Day -1
- Exposure to any investigational drug or placebo within 4 weeks of Day -1
- Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration
- Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration
- Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration
Sites / Locations
- Ppd Development, Lp
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
Bumetanide
Dapagliflozin
Bumetanide + Dapagliflozin
Arm Description
Outcomes
Primary Outcome Measures
Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs
Secondary Outcome Measures
To assess the safety and tolerability of bumetanide and dapagliflozin following multiple oral doses of 1 mg bumetanide and 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone, in healthy subjects
Explore potential pharmacodynamic (serum/urine electrolytes) effects of bumetanide + dapagliflozin following multiple doses of 1 mg bumetanide + 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone
Full Information
NCT ID
NCT00930865
First Posted
June 30, 2009
Last Updated
October 14, 2016
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT00930865
Brief Title
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Official Title
A Randomized, Open-Label, Parallel-group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bumetanide
Arm Type
Active Comparator
Arm Title
Dapagliflozin
Arm Type
Active Comparator
Arm Title
Bumetanide + Dapagliflozin
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Bumetanide
Other Intervention Name(s)
Bumex
Intervention Description
Tablets, Oral, 1 mg, Single Dose, 7 Days
Intervention Type
Drug
Intervention Name(s)
Dapagliflozin
Other Intervention Name(s)
BMS-512148
Intervention Description
Tablets, Oral, 10 mg. Single Dose, 7 Days
Primary Outcome Measure Information:
Title
Exposure to the investigational drug will be measured to compare with and without the co-administration of other drugs
Time Frame
24 hours post-dose on Day 8 and 15
Secondary Outcome Measure Information:
Title
To assess the safety and tolerability of bumetanide and dapagliflozin following multiple oral doses of 1 mg bumetanide and 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone, in healthy subjects
Time Frame
during 14 days of dosing
Title
Explore potential pharmacodynamic (serum/urine electrolytes) effects of bumetanide + dapagliflozin following multiple doses of 1 mg bumetanide + 10 mg dapagliflozin, administered together, either simultaneously or after adaptation to either agent alone
Time Frame
during 14 days of dosing
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45
Exclusion Criteria:
WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
Any significant acute or chronic medical illness
Current or recent (within 3 months) gastrointestinal disease
Current smoker or recent (within 1 month) history of regular tobacco use
Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population
Abnormal urinalysis at screening
Glucosuria at screening
Abnormal liver functions tests (ALT, AST or total bilirubin > 10 % ULN)
Presence of edema on physical exam
History of diabetes mellitus
History of heart failure
History of renal insufficiency
History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
Positive urine screen for drugs of abuse either at screening or before dosing
Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
History of allergy to SGLT2 inhibitors, bumetanide (or related compounds)
History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
Prior exposure to dapagliflozin within 3 months of Day -1
Exposure to any investigational drug or placebo within 4 weeks of Day -1
Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration
Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration
Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Ppd Development, Lp
City
Austin
State/Province
Texas
ZIP/Postal Code
78744
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
29440005
Citation
Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc. 2018 Feb 10;7(4):e007046. doi: 10.1161/JAHA.117.007046.
Results Reference
derived
Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3647&filename=MB102-057_redacted%20_CSR%20_synopsis.pdf
Description
MB102-057_redacted _CSR _synopsis
Learn more about this trial
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
We'll reach out to this number within 24 hrs